

The background features a large, abstract graphic with overlapping circles in dark blue, light blue, and pink. A faint, stylized logo is visible in the upper right. A photograph of the San Diego skyline at dusk is positioned on the right side, with the city lights reflected in the water.

ASH 2024

66th ASH Annual Meeting and Exposition

December 7–10, 2024
San Diego, US



TOP ABSTRACTS

To help navigate the exciting content being presented at the 66th American Society of Hematology (ASH) Meeting and Exposition, December 7–10, 2024, San Diego, US, the AML Hub Steering Committee have provided their recommendations for the top abstracts to look out for in AML.

ASH 2024: Top abstracts in AML

December 7–10, 2024

Saturday, December 7, 2024

Abstract	Title	Speaker	Time (PT)
55 View	A Randomized Comparison of CPX-351 and FLAG-Ida in Patients with High-Risk Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome (MDS) and MDS-Related Gene Mutations: A Subgroup Analysis of the UK NCRI AML19 Trial	Priyanka Mehta	09:30
57 View	Venetoclax Combined with “7+3” Induction Chemotherapy Induces High MRD-Negative Response Rates in Newly Diagnosed AML Patients Fit for Intensive Chemotherapy across Ages	Ioannis Mantzaris	10:00
59 View	A Randomised Comparison of CPX-351 Versus Standard Daunorubicin and Cytarabine Plus Fractionated Gemtuzumab Ozogamicin in Older Adults with AML without Adverse Risk Cytogenetics: Results of the NCRI AML18 Trial	Steven Knapper	10:30
60 View	AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial	Shai Shimony	10:45
211 View	Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia	Ibrahim Aldoss	14:00
212 View	Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations	Emma Searle	14:15
213 View	Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia	Joshua F. Zeidner	14:30
214 View	Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007	Amer M. Zeidan	14:45
215 View	Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations	Christian Recher	15:00
216 View	Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML	Ghayas C. Issa	15:15

Abstract	Title	Speaker	Time (PT)
217 View	A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial	Chong Chyn Chua	14:00
218 View	10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years	Richard M. Stone	14:15
219 View	A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update	Jennifer Marvin-Peek	14:30
220 View	Long-Term Survival Outcomes and Cytogenetic/Molecular Patterns of Relapse in Adults with FLT3-Mutated AML Receiving Frontline Triplet Therapy with a Hypomethylating Agent, Venetoclax and FLT3 Inhibitor	Nicholas J. Short	14:45
221 View	Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML	Selina Luger	15:00
227 View	Secondary Genetic Alterations and Measurable Residual Disease in Core Binding Factor Acute Myeloid Leukemia - a Study from the Acute Leukemia French Intergroup	Loic Vasseur	15:00
1500 View	EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Final Results of Dose Escalation and Optimization Cohorts from a Phase I/IIa Study in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML) or Myelodysplastic Syndrome (MDS)	David Taussig	17:30 (poster session)
1512 View	Final results of Quiwi: A double blinded, randomized Pethema trial comparing standard chemotherapy plus quizartinib versus placebo in adult patients with newly diagnosed FLT3-ITD negative AML	Pau Montesinos	17:30 (poster session)
1564 View	Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial	Uma Borate	17:30 (poster session)
2425 View	Real-World Treatment Patterns and Outcomes with Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia	Pramila Krishnamurthy	17:30 (poster session)

Sunday, December 8, 2024

Abstract	Title	Speaker	Time (PT)
6 View	Impact of Socioeconomic Factors on Access to and Outcomes of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Acute Myeloid Leukemia (AML): A Multi-Center Observational Study	Natalie Wuliji	14:00
446 View	Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine	Ian M. Bouligny	09:45
2875 View	Active Immunotherapy with Vididencel As Maintenance Treatment in MRD+ AML Patients in CR1 Results in Strong Anti-Tumor Immune Responses and Durable Long-Term Survival in Patients with an Immune Competent Immune Profile	Arjan A. van de Loosdrecht	18:00 (poster session)
2877 View	Phase 2a Study of SLS009, a Highly Selective CDK9 Inhibitor, in Combination with Azacitidine and Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia after Prior Venetoclax Treatment	Joshua F. Zeidner	18:00 (poster session)
2883 View	Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials	Jennifer Marvin-Peek	18:00 (poster session)
2889 View	Timing of Response with Gilteritinib Monotherapy in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia	Jianxiang Wang	18:00 (poster session)
2890 View	Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication “Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx)	Mark J. Levis	18:00 (poster session)

Monday, December 9, 2024

Abstract	Title	Speaker	Time (PT)
733 View	Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial	Daniel J. DeAngelo	10:30
737 View	Preliminary Safety, Efficacy, and Molecular Characterization of Emavusertib (CA-4948) in Relapsed/Refractory Acute Myeloid Leukemia Patients	Eric S. Winer	11:30
778 View	Multicenter, Real-World Experience Study of FLT3-Inhibitor Post-Transplant Maintenance Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia with FLT3-ITD	Yomna Eissa	11:15

Abstract	Title	Speaker	Time (PT)
848 View	Correlation of Baseline Gene Mutations With Quizartinib Efficacy in Patients With FLT3-ITD Positive Newly Diagnosed Acute Myeloid Leukemia in the Phase 3 QuANTUM-First Trial	Mark J. Levis	15:00
967 View	A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO – a Report from the Children’s Oncology Group	Todd M Cooper	16:30
968 View	Favourable Outcomes in Newly Diagnosed Paediatric AML with Gemtuzumab Ozogamicin and Risk-Stratified Therapy: Results from the International Phase III Myechild 01 Trial	Brenda Gibson	16:45
969 View	Venetoclax Plus Azacitidine for Newly Diagnosed Younger Acute Myeloid Leukemia Patients Independent of Fitness for Intensive Chemotherapy	Daniel A Pollyea	17:00
970 View	A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) – Topline Results	Agnieszka Wierzbowska	17:15
971 View	Venetoclax and Decitabine Compared with Standard Intensive Chemotherapy As Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia: Updated Results of a Multicenter, Randomized, Phase 2b Trial	Jing Lu	17:30
972 View	High-Dose Cytarabine with Idarubicin Versus High-Dose Cytarabine within First Consolidation for Acute Myeloid Leukemia in First Complete Remission: An Open-Label, Multicenter, Randomized, Phase 3 Trial	Zinan Feng	17:45
4255 View	Phase 1 Safety and Efficacy of Tuspentinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspentinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML	Naval Daver	18:00 (poster session)
4256 View	Randomized Phase II Trial of Dendritic Cell/AML Fusion Cell Vaccination Compared to Standard of Care Therapy in AML CR1	Prateek Pophali	18:00 (poster session)
4278 View	Quantum-First: Deep-Dive Analysis of FMS-like Tyrosine Kinase “Internal Tandem Duplication (FLT3-ITD) Detection Methods Utilized for Enrollment and Longitudinal MRD Detection in Newly Diagnosed (nd) Patients (pts) with FLT3-ITD” Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)	Jaime E. Connolly Rohrbach	18:00 (poster session)
4324 View	Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age	Uma Borate	18:00 (poster session)



#ASH24

Follow us on X to keep up to date
with the latest from the congress

@AML_Hub



Brought to you by

